Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.3M Buy
807,076
+100,579
+14% +$2.22M ﹤0.01% 2428
2026
Q1
$10.3M Buy
706,497
+232,422
+49% +$3.41M ﹤0.01% 3211
2025
Q4
$5.99M Sell
474,075
-177,320
-27% -$2.62M ﹤0.01% 4009
2025
Q3
$10M Buy
651,395
+36,793
+6% +$593K ﹤0.01% 3269
2025
Q2
$9.66M Buy
+614,602
New +$9.32M ﹤0.01% 3077
2024
Q3
Sell
-3
Closed -$85 15105
2024
Q2
$78 Buy
+3
New +$62 ﹤0.01% 14104
2024
Q1
Sell
-1,841
Closed -$39.5K 15344
2023
Q4
$42.8K Buy
+1,841
New +$37K ﹤0.01% 11948
2023
Q3
Sell
-44,282
Closed -$872K 15001
2023
Q2
$1M Sell
44,282
-76,046
-63% -$1.53M ﹤0.01% 6449
2023
Q1
$2.36M Sell
120,328
-8,395
-7% -$161K ﹤0.01% 5042
2022
Q4
$2.21M Buy
+128,723
New +$2.28M ﹤0.01% 5287

Other funds holding RXO

Citadel Advisors's RXO Position: Q2 2026 in Review

Citadel Advisors increased its RXO (RXO) stake by 14% in Q2 2026, buying an estimated $2.22M and bringing the position to 807,076 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

Citadel Advisors first reported a position in RXO in Q4 2022 and has held it in 10 quarters since. 303 funds tracked by Wall St. Rank hold RXO as of Q2 2026.

  • Citadel Advisors held 807,076 shares of RXO worth $22.3M as of Q2 2026.
  • Citadel Advisors bought 100,579 RXO shares in Q2 2026, an estimated $2.22M.
  • RXO made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2428 holding.
  • Citadel Advisors first reported a position in RXO in Q4 2022 and has held it in 10 quarters since.
  • 303 funds tracked by Wall St. Rank held RXO as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.